Lower In-Hospital Mortality Linked to In-Hospital Statin Exposure

Why It Matters

The findings suggest that continuing or initiating statins during acute illness could reduce short‑term mortality in frail older patients, potentially reshaping geriatric care protocols.

Key Takeaways

• 23.5% of 545 geriatric patients received in-hospital statins.
• In-hospital mortality: 8.6% statin users vs 14.9% non‑users.
• Adjusted odds ratio for mortality with statins: 0.50 (95% CI 0.3‑1.0).
• Study limited by observational design and small sample size.
• Findings suggest statins may benefit acute geriatric patients.

Pulse Analysis

Statins have long been a cornerstone of cardiovascular risk management, reducing the incidence of myocardial infarction, stroke, and related mortality across age groups. In older adults, especially those over 75, the balance between benefit and tolerability has been scrutinized, with registry data showing comparable relative risk reductions to younger cohorts. Yet, the question of whether short‑term statin exposure during an acute hospital stay can influence immediate outcomes has remained largely unanswered. Moreover, the safety profile of statins in the frail elderly has been reinforced by recent pharmacovigilance studies.

The recent retrospective analysis published in Acta Clinica Belgica examined 545 patients admitted to an acute geriatric ward between December 2022 and July 2023. Approximately 23.5 % received a statin on the second day of admission, and in‑hospital mortality fell to 8.6 % among these patients versus 14.9 % in non‑users. After adjusting for age, comorbidities, functional status and prior cardiovascular disease, statin exposure was associated with a 50 % reduction in the odds of death (adjusted OR 0.50, 95 % CI 0.3‑1.0), a signal that persisted across primary and secondary prevention subgroups. The absolute risk reduction translated to a number needed to treat of roughly 16 patients to prevent one death.

Because the study is observational, causality cannot be confirmed, and residual confounding may still influence the findings. The modest sample size and lack of data on pre‑hospital statin use further limit generalizability. Nonetheless, the results raise the prospect that maintaining or initiating statin therapy during acute illness could be a low‑cost strategy to improve geriatric outcomes, prompting calls for prospective randomized trials to define optimal dosing, timing, and patient selection.